1FW

AUG 1 5 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/676.999 Filing Date TRANSMITTAL October 1, 2003 First Named Inventor **FORM** DINH, Thomas Q. et al. Art Unit 3731 **Examiner Name** SWEET, Thomas (to be used for all correspondence after initial filing) Attorney Docket Number PA1289 CIP Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC 1 Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Return Postcard Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Medtronic Vascular, Inc Signature Printed name Alan M. Krubiner Date Reg. No. August 12, 2005 26,289 **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date Kimberly Melvin August 12, 2005 Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## CERTIFICATE OF MAILING (37 C.F.R. § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in the envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 12, 2005.

By: Kimberly Melvin

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

10/676,999

Confirmation No.:

7261

**Applicant** 

DINH, Thomas Q.

Filed

October 1, 2003

TC/A.U.

3738

Examiner

SWEET, Thomas

Docket No.

**PA1289 CIP** 

Customer No.

28390

Title

DRUG-ELUTING STENT FOR CONTROLLED DRUG DELIVERY

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **AMENDMENT**

Sir:

In response to the Office Action mailed July 15, 2005, the applicants hereby elect to prosecute Group I (claims 1-25) without traverse. Applicants further elect to prosecute on the merits species A (Figure 2). Claims 1-10 and 12-25 read on this species. Non-elected Claims 26-34 are withdrawn from consideration.

Amendments to the Claims are reflected in the listing of claims which begin on page two (2) of this paper.

Remarks/Arguments begin on page seven (7) of this paper.